We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Martin Okun

Martin M Okun MD, PhD

Dermatologist, Fort HealthCare, Fort Atkinson, Wisconsin

Dr. Okun is a board-certified dermatologist practicing medical and surgical dermatology in southeastern Wisconsin. From 2005-2015, he was employed by Abbott Laboratories/AbbVie Inc., where he worked in dermatology medical affairs and clinical development. Dr. Okun was on the teams that successfully developed HUMIRA for treatment of adult psoriasis, pediatric psoriasis (ex-US), and hidradenitis suppurativa (HS). He was instrumental in developing clinical trial designs and novel clinical endpoints for the Phase 2 and 3 HS trials, functioned as a medical monitor for one of the Phase 3 trials, and coauthored the regulatory documents that were used for HS submission to regulatory agencies. Dr. Okun has coauthored more than 20 articles on psoriasis and HS.

Disclosures

Dr. Okun is a former employee, current consultant, and member of speakers bureau for AbbVie.

He is a consultant for Azora, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Ichnos, Incyte, InflaRx, Innovaderm, Genentech, Pfizer, Reistone, Seattle Genetics, and UCB.